Drug Farm Raises $27M USD Financing for Advancement of First-In-Class Hepatitis B and Cardiovascular-Renal Drugs into Clinical Trials

Drug Farm, a private biotechnology company utilizing genetics and AI technologies to discover and develop innovative, immune-modulating therapies, has raised the first round of C series financing totaling $27 million USD. With this financing round, Drug Farm will continue its clinical program on DF-006 and advance DF-003 into a first-in-human clinical trial.